Clearing the AI drug discovery bottleneck
Case study: AI-driven drug discovery is producing candidates faster than the clinical trial ecosystem can absorb them. Too many AI-discovered compounds, not enough places to run Phase 1 — sponsors have a validated candidate and investor conviction, but nowhere near enough access to patients and sites to get the molecule into the clinic and generate the early biomarker data that proves the thesis.
Solution: AllianceXPartners gives AI-native drug discovery companies direct access to Phase 1 trial capacity and patient populations — including our own Phase 1 units — alongside our partner network, paired with biomarker-driven endpoints that deliver early, capital-efficient signals of efficacy before a sponsor commits to a full program. We’re built to turn AI-generated candidates into real clinical evidence — fast.
Rescuing clinical stage assets
Case study: A Phase 3 trial missed its primary endpoint overall, but demonstrated a meaningful signal in a defined sub-population. The FDA indicated a potential path forward — yet the U.S. company only had sufficient cash to fund part of the confirmatory program.
Solution: AllianceXPartners structures and coordinates a complementary confirmatory trial, co-run by AXP’s local partners in the target territory alongside the sponsor’s U.S. trial activities. AXP’s partners lead execution in their respective territory, while the programs are designed to complement one another and collectively support the regulatory and filing strategy. This allows the sponsor to advance the asset toward a filing without having to fully fund the global confirmatory program itself.
Hundreds of biotechs are stuck in the same trap
The 2021–2025 biotech downturn created an unusually deep pool of stranded late-stage assets. Some companies saw Phase 3 trials miss their primary endpoints despite compelling efficacy in defined subpopulations. Others became “zombie biotechs,” trading at or below cash with promising programs but no capital to advance them. The recurring pattern is clear:
a viable FDA path forward — and no money to pursue it
Completed clinical trials. Everybody wins.
Rather than simply financing corporate survival, we fund the work that can create enterprise value: a confirmatory clinical trial designed to reach a decisive regulatory and commercial inflection point. In parallel, our structure can open access to foreign markets, creating the potential for earlier commercialization and royalty revenue. A successfully completed trial can materially de-risk the asset, increase the company’s strategic value, strengthen its negotiating position, and create a credible path toward partnership or acquisition by Big Pharma.
The difference is simple: traditional rescue capital keeps the company alive. We aim to move the asset forward — from stranded program to validated, revenue-generating, acquisition-ready opportunity.
Who gets what
US Biotech
Grants a royalty, a warrant and EAEU rights.
Gets a fully funded pivotal trial and FDA-usable data — at zero cash cost.
AllianceXPartners
Origination, structuring, clinical, regulatory and data governance.
Takes a royalty, warrant, services margin and EAEU royalty.
EAEU Pharma Partner
Funds the confirmatory trial and provides local regulatory sponsorship.
Gets exclusive EAEU rights to an approvable drug.
Built for every stakeholder in the trial
Biotech Innovators
Turn a stranded Phase 3 into a funded confirmatory trial — without giving up US and rest-of-world rights.
EAEU Pharma Partners
Secure exclusive regional rights to a de-risked, near-approval asset by funding its confirmatory trial.
Investors
A royalty-aggregator platform built at near-zero capital cost, orchestrating value instead of buying it.
One protocol.
Two compliant tracks.
AllianceXPartners designs every trial as a two-track, multi-regional protocol: an FDA track across US/EU/ICH and non-restricted EAEU states, and a separate EAEU registration track.
News & Updates
Let’s talk.
Biotech innovator, EAEU pharma partner, clinical site or investor — we want to hear from you.
